Lamm WLG, Solares SM, Vivieros EJM, Mata MP, Pacheco GC, Calderón FF

Language: Spanish
References: 12
Page: 385-393
PDF size: 68.53 Kb.

ABSTRACT

Introduction. Different androgen deprivation modalities for advanced prostate cancer exist, which include the use of LHRH analogs, bilateral orquiectomy, or antiandrogens, used alone or in combination. Material and methods. 138 patients with advanced prostate cancer treated with androgen deprivation. We evaluated the percentage of dependent hormone patients, time to disease progression due to risk factors, and efficiency of the treatment response by determination of the decreased percentage of the initial PSA. Results. We observed a 96.3% overall response to androgen. The overall decreased percentage of the initial PSA was of 91.2%. Monotherapy was more efficient than total androgen deprivation (p = 0.001). Hormone refractory patients with high risk factors progressed earlier (13.9 months) and with a less decreased percentage of the initial PSA (78.5%). Bone metastasis, Gleason score and those initially treated with total androgen deprivation showed an earlier progression. 62% of those treated with ketoconazol plus prednisone showed an initial good response, but its duration was short and with a survival time of 5.56 months. Conclusions. Androgen deprivation is effective for advanced prostate cancer. The predictive factors for disease progression were bone metastasis, Gleason score and decreased percentage of the initial PSA.

REFERENCES

1. Huggins C, Hodges CV. Studies on prostate cancer: The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.

2. Israeli RS, Miller WN, Su SL, et al. Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the –polymerase chain reaction. J Urol 1995; 153: 573-7.

3. Denis L, Griffiths K. Endocrine treatment in prostate cancer. Sem Urol Onc 2000; 18: 52-74.

4. Coffey DS, Smolev J, Heston WDW, et al. Growth characteristics and immunogenecity of the R-3327 rat prostate carcinoma. NCI Monogr 1974; 49: 289-91.

5. Labrie F, DuPont A, Belanger A. Complete androgen blockade for the treatment of prostate carcinoma. In: DeVita VT, Hellman S, Rosenberg SH (Eds.). Important Advances in Oncology. Philadelphia, PA: Lippincott; 1985, pp. 193-217.

6. Huggins C, Scott W. Bilateral adrenalectomy in prostatic cancer. Ann Surg 1945; 122: 1031-41.

7. Labrie F, DuPont A, Belanger A. New approach in the treatment of prostatic cancer. Complete instead of partial withdrawal of androgens. Prostate 1983; 4: 579-94.

8. Siroky M, Edelstein R, Krane R. Manual of Urology 1999; 204-6.

9. Newling D. Antiandrogens in the treatment of prostate cancer. B J Urol 1996; 77: 776-84.

10. 10.Isaacs J, Coffey D. Androgenic control of prostatic growth, regulation of steroid levels. Geneva. UICC. Prostate Cancer 1979; 48: 112-22.

11. 11.Rosen MA. Impact of prostate specific antigen screening on the natural history of prostate cancer. Urol 1995; 4: 757-68.

12. 12.William O, Kantoff P. Management of hormone refractory prostate cancer: current standars and future prospects. J Urol 1998; 160: 1220-9.